Testicular germ cell tumours

aka Seminoma, Non-seminomatous germ cell tumour, NSGCT

Testicular germ cell tumours are the most curable adult solid cancer. Cisplatin-based chemotherapy cures the large majority of even widely spread disease; today's research is about giving less treatment to the many while rescuing the few who relapse.

Testicular germ cell tumours (GCTs) are seminomas or non-seminomas (embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma, mixed), arising from germ cell neoplasia in situ, almost universally carrying 12p gain (i(12p)). Serum tumour markers (AFP, hCG, LDH) stage and monitor the disease; miR-371a-3p is a more sensitive marker entering practice. The IGCCCG classification (1997, updated 2021) divides metastatic disease into good, intermediate and poor prognosis with 5-year survival of ~95%, ~90% and ~65-70%.

Orchiectomy is followed by surveillance for most stage I disease; adjuvant carboplatin (seminoma) or one cycle of BEP (non-seminoma) are options for high-risk stage I. Metastatic disease receives BEP ×3 (good risk) or ×4 (intermediate/poor), or EP ×4 when bleomycin is contraindicated; residual masses after chemotherapy in non-seminoma are resected (retroperitoneal lymph node dissection). Relapse is treated with conventional-dose salvage (TIP, VeIP) or high-dose chemotherapy with autologous stem-cell rescue (TI-CE); the TIGER trial directly compares these. Survivorship (cardiovascular risk, second cancers, hypogonadism, infertility, ototoxicity, neuropathy) is a central concern because patients live 50+ years after cure.

State of the art today

miR-371a-3p promises to replace marker-negative uncertainty with a sensitive blood test for viable disease.
High-dose chemotherapy cures a substantial fraction of relapsed patients; TIGER will define its place.
Poor-risk disease and platinum-refractory GCT remain the unsolved minority; immunotherapy failed here.

Show survival figures (1)

Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.

Cure rates above 95% are the benchmark for what chemotherapy can do; the field now works on de-escalation (surveillance for stage I, single-cycle adjuvant therapy) and survivorship.

Who it affects

The most common cancer in men aged 15-40; about 75,000 cases per year worldwide (GLOBOCAN) with cure rates above 95% overall and ~80% even in metastatic disease.

Group

genitourinary

Where the cases are

Cases by country · GLOBOCAN 2022

All countries →

No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.

Standard of care

5top

Stage I seminoma

Orchiectomy then surveillance (preferred); adjuvant carboplatin AUC 7 ×1 or para-aortic radiotherapy for those declining surveillance.

NCCN · Category 2A (surveillance preferred)

CarboplatinActive surveillance

Stage I non-seminoma

Surveillance (relapse ~15-50% by LVI status, all salvageable); or BEP ×1 or nerve-sparing RPLND for high-risk.

NCCN · Category 2A

BleomycinEtoposideCisplatinActive surveillance

Metastatic, IGCCCG good risk

BEP ×3 or EP ×4; post-chemotherapy RPLND for residual non-seminoma masses >1 cm.

NCCN · Category 1

BleomycinEtoposideCisplatin

Metastatic, intermediate/poor risk

BEP ×4 (or VIP if bleomycin contraindicated); early marker-decline assessment to intensify (GETUG-13); brain metastases treated multimodally.

NCCN · Category 1

BleomycinEtoposideCisplatinIfosfamide

Relapsed

TIP or VeIP conventional-dose salvage, or high-dose carboplatin-etoposide with autologous stem-cell rescue (TI-CE); TIGER phase 3 compares the two; late relapse and teratoma need surgery.

NCCN · Category 2A

Paclitaxel / nab-paclitaxelIfosfamideCisplatinCarboplatinEtoposideAutologous stem cell transplant (high-dose therapy)

Subtypes & biomarkers

top

Subtypes

Seminoma
Non-seminoma : embryonal carcinoma, yolk sac, choriocarcinoma, teratoma, mixed
Germ cell neoplasia in situ (precursor)
Extragonadal (mediastinal, retroperitoneal) GCT
Spermatocytic tumour (older men, indolent)

Biomarkers clinicians test

AFP, hCG, LDH (S stage; IGCCCG risk)
miR-371a-3p (emerging, high sensitivity for viable GCT)
i (12p) / 12p gain
Rete testis and lymphovascular invasion (stage I risk)
Tumour size >4 cm (seminoma stage I risk)

Target prevalence in this cancer

Target / alteration	Prevalence	Measure	Source
Claudin 6	90%	IHC positivity

How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.

History

8top

1960Li and colleagues: actinomycin D, methotrexate and chlorambucil active in GCT
MethotrexateDactinomycin (actinomycin D)
1974Einhorn introduces cisplatin (PVB)
Cure rates in metastatic disease jump from ~10% to ~60-70%.
Cisplatin
1987BEP replaces PVB (Williams, NEJM)
Etoposide substitutes vinblastine with better efficacy and less neurotoxicity.
EtoposideBleomycin
1989BEP ×3 sufficient for good-risk disease (Einhorn)
1997IGCCCG prognostic classification
Updated in 2021 with LDH and age refinements.
2005Carboplatin ×1 equals radiotherapy for stage I seminoma (MRC TE19)
Carboplatin
2014Surveillance becomes standard for stage I
2019miR-371a-3p validated as a serum marker (Dieckmann, JCO)

Pipeline

2top

ApprovedCytotoxic chemotherapy (platinum)

Carboplatin

Autologous stem cell transplant (high-dose therapy)

Open problems

Platinum-refractory disease has no effective therapy; checkpoint inhibitors were inactive.
Late effects of cisplatin (cardiovascular disease, second cancers, hearing loss) in men cured in their 20s.
Over-treatment of stage I disease without reliable predictors.
Access to high-dose chemotherapy and expert RPLND outside specialist centres.

Trials

top

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov

Testicular germ cell tumours

condition: Testicular germ cell tumor

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Expert centres

top

Where the expertise is

Centres linked to this cancer in OnCo

Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, IN, USNCI comprehensive
via this cancer, Cisplatin
Alliance for Clinical Trials in OncologyChicago, IL, US
via Carboplatin
German Breast Group (GBG)Neu-Isenburg, DE
via Carboplatin
Institute of Oncology LjubljanaLjubljana, SI
via Carboplatin

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost.

Questions to ask

top

Bring to your appointment

Questions to ask your oncologist about Testicular germ cell tumours

Generated from this cancer's standard of care, biomarkers, and pipeline · 19 questions

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?
Why: Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example AFP, hCG, LDH, miR-371a-3p, i/ 12p gain, Rete testis and lymphovascular invasion, Tumour size >4 cm), and what were the results?
Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?
Why: Recognised subtypes for this cancer include Seminoma, Non-seminoma: embryonal carcinoma, yolk sac, choriocarcinoma, teratoma, mixed, Germ cell neoplasia in situ.
Is germline (inherited) genetic testing recommended for me or my family?
Why: Inherited variants can change treatment and matter for relatives.

Stage I seminoma

For my situation (stage i seminoma), which of the standard options do you recommend and why?
Why: Guideline options include: Orchiectomy then surveillance (preferred); adjuvant carboplatin AUC 7 ×1 or para-aortic radiotherapy for those declining surveillance.
Am I a candidate for Carboplatin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Stage I non-seminoma

For my situation (stage i non-seminoma), which of the standard options do you recommend and why?
Why: Guideline options include: Surveillance (relapse ~15-50% by LVI status, all salvageable); or BEP ×1 or nerve-sparing RPLND for high-risk.
Am I a candidate for Bleomycin, Etoposide, Cisplatin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Metastatic, IGCCCG good risk

For my situation (metastatic, igcccg good risk), which of the standard options do you recommend and why?
Why: Guideline options include: BEP ×3 or EP ×4; post-chemotherapy RPLND for residual non-seminoma masses >1 cm.
Am I a candidate for Bleomycin, Etoposide, Cisplatin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Metastatic, intermediate/poor risk

For my situation (metastatic, intermediate/poor risk), which of the standard options do you recommend and why?
Why: Guideline options include: BEP ×4 (or VIP if bleomycin contraindicated); early marker-decline assessment to intensify (GETUG-13); brain metastases treated multimodally.
Am I a candidate for Bleomycin, Etoposide, Cisplatin or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Relapsed

For my situation (relapsed), which of the standard options do you recommend and why?
Why: Guideline options include: TIP or VeIP conventional-dose salvage, or high-dose carboplatin-etoposide with autologous stem-cell rescue (TI-CE); TIGER phase 3 compares the two; late relapse and teratoma need surgery.
Am I a candidate for Paclitaxel / nab-paclitaxel, Ifosfamide, Cisplatin or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Any stage

Are there clinical trials I could join, for example of Autologous stem cell transplant (high-dose therapy), Carboplatin?
Why: Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?
Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Why: Supportive care improves quality of life and helps patients complete treatment.
I read that “Platinum-refractory disease has no effective therapy; checkpoint inhibitors were inactive”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.
I read that “Late effects of cisplatin (cardiovascular disease, second cancers, hearing loss) in men cured in their 20s”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.